Calvo Felipe A, Krengli Marco, Asencio Jose M, Serrano Javier, Poortmans Philip, Roeder Falk, Krempien Robert, Hensley Frank W
Department of Oncology, Clínica Universidad de Navarra, Madrid, Spain; School of Medicine, Complutense University, Madrid, Spain.
Radiotherapy Unit, Department of Translation Medicine, University of Piemonte Orientale, Novara, Italy.
Radiother Oncol. 2020 Jul;148:57-64. doi: 10.1016/j.radonc.2020.03.040. Epub 2020 Apr 8.
Radiation therapy (RT) is a valuable component of multimodal treatment for localized pancreatic cancer. Intraoperative radiation therapy (IORT) is a very precise sub-component of RT that can intensify the irradiation effect for cancer involving an anatomically well-defined volume, generally delivered with electrons (IOERT). Unresectable disease categories benefit from dose-escalated chemoradiation strategies in the context of active systemic therapy and potential radical surgery. Prolonged preoperative treatment may act as a filter for selecting patients with occult resistant metastatic disease. Long-term survivors were observed among unresected patients treated with external beam RT and an IOERT boost (OS 6% at 3 years; 3% >5 years). Improvement of local control through higher RT doses has an impact on the survival of patients with a lower tendency towards disease spread. IOERT is a well-accepted asset in the clinical scenario (maturity and reproducibility of results, albeit of low official level of evidence) and extremely accurate in terms of dose-deposit characteristics and normal tissue sparing. It is a technique that can be integrated with systemic therapy and surgical progress. International guidelines (National Comprehensive Cancer Network or NCCN guidelines) currently recommend the use of IOERT in cases of close surgical margins and residual disease. We report the ESTRO/ACROP recommendations for performing IOERT in unresected pancreatic cancer.
放射治疗(RT)是局部胰腺癌多模式治疗的重要组成部分。术中放射治疗(IORT)是放射治疗中一种非常精确的子组件,可增强对涉及解剖结构明确体积的癌症的照射效果,通常使用电子进行(术中电子放射治疗,IOERT)。在积极的全身治疗和潜在的根治性手术背景下,不可切除疾病类别可从剂量递增的放化疗策略中获益。延长术前治疗可作为筛选隐匿性耐药转移性疾病患者的一种手段。在接受外照射放疗和IOERT增强治疗的未切除患者中观察到长期生存者(3年总生存率为6%;5年以上为3%)。通过提高放疗剂量改善局部控制对疾病扩散倾向较低的患者的生存有影响。IOERT在临床应用中是一种被广泛接受的方法(结果的成熟度和可重复性,尽管官方证据水平较低),在剂量沉积特性和正常组织保护方面极其精确。它是一种可与全身治疗和手术进展相结合的技术。国际指南(美国国立综合癌症网络或NCCN指南)目前建议在手术切缘接近和有残留疾病的情况下使用IOERT。我们报告了欧洲放射肿瘤学会/希腊放射肿瘤学会关于在未切除胰腺癌中进行IOERT的建议。